News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 

Two new treatments funded for Parkinson’s disease

Media release

Two new treatments funded for Parkinson’s disease

Two new treatments will be subsidised from 1 November for people with Parkinson’s disease, government drug-funder PHARMAC announced today.

Ropinirole (Requip) and entacapone (Comtan) provide alternatives to treatments that are already funded, but which can cause serious side effects in some patients.

Ropinirole provides an alternative to drugs such as pergolide, which may increase the risk of heart valve problems for some patients, while entacapone can be used in place of tolcapone, which needs close monitoring of liver function by a specialist.

PHARMAC Chief Executive Wayne McNee says listing the two drugs is good news for people with Parkinson’s disease, and adds to the 12 treatments already funded.

“We’re pleased to be able to make more funded options available,” says Wayne McNee.

“The treatments that are already subsidised will continue to be effective and used by a considerable number of patients. But these decisions mean there will now be more funded options available, which is good news for patients and clinicians.”

Ropinirole is a dopamine agonist that acts to reduce the symptoms of Parkinson’s disease, including tremors (shaking) and slowness of movement. It can be taken on its own.

Entacapone is only used as a combination treatment. It acts to increase the duration that levodopa-based treatments are effective.

Wayne McNee says there are about 12,000 people taking subsidised anti-Parkinson’s agents, although only about 2000 of these are taking the comparable treatments to those being listed on 1 November.
PHARMAC estimates the new treatments will add $2.4 million to pharmaceutical spending over the next five years.

The decisions are the latest announced by PHARMAC as it continues its new investments programme. Recent decisions including widening access to salmeterol for asthma, alendronate for osteoporosis, mycophenolate for transplants, and the aromatase inhibitors for breast cancer.

ENDS

© Scoop Media

 
 
 
Culture Headlines | Health Headlines | Education Headlines

 


Howard Davis: Joel Coen's Monochromatic Macbeth

The Bard of Avon may well be smirking up the sleeves of his lace doublet at the irony of Will Smith's Oscar debacle, but now that the initial furore has dissipated, it's worth revisiting the movie for which Denzel Washington was also nominated. More>>

Howard Davis: Kenneth Branagh’s Black & White Belfast

Branagh has assembled a wonderful cast, including Ciarán Hinds, a gently formidable actor who well deserves his Oscar nomination, and Judi Dench, who steals every scene she’s in. More>>


Howard Davis: Dennis Villeneuve’s Dune - A Brief History

So many elements of Herbert’s novel have since become tropes of popular SciFi that Villeneuve’s film sometimes seems deceptively derivative. What makes all this nonsense essential viewing is his astonishing visual sensibility. More>>


Howard Davis: Jill Trevelyan's Rita Angus

Although Angus has become one of Aotearoa’s best-loved painters, the story of her life remained little known and poorly understood before Jill Trevelyan's acclaimed and revelatory biography, which has been republished by Te Papa press. More>>

 
 
 
 
 
 

LATEST HEADLINES

  • CULTURE
  • HEALTH
  • EDUCATION
 
 
  • Wellington
  • Christchurch
  • Auckland